Psilocybin and MDMA FDA Approval 2026: Where the Psychedelic Pipeline Stands After Makary's Resignation

# Psilocybin and MDMA FDA Approval 2026: Where the Psychedelic Pipeline Stands After Makary's Resignation

> **Quick answer:** As of May 2026, psilocybin and methylone (an MDMA analog) are not FDA approved — but they are closer than ever. The FDA awarded National Priority Review Vouchers in April 2026 to three companies, compressing review timelines to 1-2 months. Then, on May 12, FDA Commissioner Marty Makary resigned after a dispute over flavored vape approvals. His replacement, acting commissioner Kyle Diamantas, has no public record on psychedelic policy — creating uncertainty for a pipeline that was just gaining momentum.

Psilocybin MDMA FDA approval in 2026 was looking like a genuine near-term possibility — until the most psychedelic-friendly FDA commissioner in modern history walked out the door. Makary had listed "new psychedelic guidance" among his 50 major FDA reforms. Now the agency has a food lawyer in the chair, an executive order gathering dust, and millions of treatment-resistant depression and PTSD patients asking the same question: what just happened to my treatment options?

This article is for informational purposes only and does not replace professional medical advice. Consult a healthcare provider for medical concerns.

## What Makary Actually Did for Psychedelics — and Why It Matters

Marty Makary, who resigned on May 12, 2026 after White House staff signed off on a plan to replace him, had done more for the psychedelic drug pipeline than any previous FDA commissioner. His resignation letter — widely circulated as a text message screenshot — listed "guidance for advancing psychedelic agents" as one of his personal flagship accomplishments alongside faster drug reviews and a rare-disease approval pathway.